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ABstrACt
Objectives: High grade serous ovarian cancer (HGSC) is the most common type of ovarian cancer and is responsible for about 
90% of ovarian cancer deaths. The diagnostic tests currently used do not increase the detection rates for ovarian cancer. 
There is a great necessity to develop new and non-invasive diagnostic tests for ovarian cancer (OC). Cervico-vaginal fluid 
(CVF) seems to be a potential and valuable source of biomarkers for genital tract diseases including ovarian cancer. The 
aim of our pilot study was to undertake a preliminary proteomic analysis of CVF derived from ovarian cancer patients and 
to compare these with results from a control group.
Material and methods: We analysed and compared samples from a group of ovarian cancer patients and a control group 
of healthy patients. The study used MALDI-TOF coupled with nanoLC and ClinProTools software for MS, MS/MS spectra 
collection and proteomic analysis. 
results: We identified 404 different proteins in the OC group and 417 proteins in the control group. 239 of the proteins were 
found to be common to both study groups, 165 proteins were unique to the OC subjects, and 178 proteins were unique 
to the control subjects. We selected three proteins as the OC markers with the greatest potential: cysteine-rich secretory 
protein 3, fibronectin and Ly6/PLAUR domain-containing protein 3. 
Conclusions: The proteins we selected seem to possess great potential as markers for the screening and early detection of 
OC, especially in non-invasive and low-cost diagnostic tests. However, our findings require more advanced and validated 
proteomic analysis to confirm the suitability of the selected proteins in everyday medical diagnoses. 
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INtrODUCtION
High grade serous ovarian cancer (HGSC) is the most 
common type of ovarian cancer and is responsible for about 
90% of ovarian cancer deaths [1]. Early detection of cancers, 
especially of serous ovarian cancer, is necessary to reduce 
mortality rates. Until now, various diagnostic tests and tu-
mor markers have been used, but they have not increased 
the detection of the disease. A randomized study of the 
applicability and efficacy of these tests in postmenopausal 
women for ovarian cancer screening showed no reduction 
in mortality [2, 3]. It is therefore necessary to seek new tu-
mor markers from body secretions other than blood serum. 
Cervico-vaginal fluid (CVF) is a potential source of biomark-
ers for genital tract diseases. It is easily available, and so it 
is possible to use it in repeatable, inexpensive and non-in-
vasive tests. CVF is a complex body secretion consisting of 
a mixture of plasma proteins, inflammatory cells, enzymes 
and genital tract epithelial cells. The body’s physiological 
and disease states are reflected in the proteomic profiles 
characteristic of CVFs [4]. Determining the proteomic pro-
file for ovarian cancer may allow the identification of new 
markers of the early stages of this disease.
The aim of our pilot study was to undertake a proteomic 
analysis of cervico-vaginal fluid in patients with ovarian can-
cer and to compare the results with those derived from 
a healthy control group. The study attempted to compare 
the protein patterns of the ovarian cancer subjects with 
those of the control group, and in addition, to identify the 
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proteins that differentiated the ovarian cancer patients from 
the healthy subjects. 
MAtErIALs AND MEthODs
study group
The total study group comprised eleven patients with 
a median age of 57 (range 35–76) admitted to the Gyneco-
logic Oncology Department of Poznan University of Medical 
Sciences. Inclusion criteria in the cancer group: a patient 
with suspected ovarian cancer, prior to surgical treatment, 
with an open cervical os, with confirmed ovarian cancer di-
agnosis after surgery.The cancer group comprised seven 
patients with advanced ovarian cancer (5 GRADE 3 serous OC, 
2 GRADE 2 mucinous OC) and one patient with a borderline 
tumor of the ovary. Inclusion criteria in the control group: 
healthy patients without any oncological disease, no changes 
in ultrasound in the uterus and ovaries.The control group 
comprised three healthy patients who had been admitted 
because of urine incontinence. Informed written consent was 
obtained from each patient. The study was approved by the 
Poznan Univeristy of Medical Sciences Bioethical Commission.
sample processing
Cervico-vaginal fluid samples were obtained from each 
patient by placing a sterile swab into the cervical canal for 
10 seconds until saturation. The swab was removed and placed 
directly into a sterile tube containing 2 mL of 0.9% NaCl. The 
sample was then centrifuged at 3000 g for 10 minutes, and the 
supernatant was collected and stored at -80°C. The Bradford 
method was used for the determination of total protein con-
centration in each sample that we analyzed from the cancer 
group and the control group. The sample processing for MS/MS 
analysis was strictly correlated with the data received from the 
Bradford method analyses, to obtain a constant concentration 
of proteins (20 µg/mL) for all the vaginal fluid samples we ana-
lyzed. Thereafter 10mL of each vaginal fluid sample was trans-
ferred to a 0.5mL Eppendorf tube, and 15 µL of ammonium 
bicarbonate solution (50 mM) plus 1.5 µL of DDT (100 mM) were 
added. The mixture was incubated for 5 minutes at 95°C. After 
cooling to room temperature, we added 3 µL of iodoacetamide 
(100 mM) to the reaction mixture and incubated in the dark 
for 20 minutes at room temperature. After this incubation, 
we added 3 µL of trypsin enzyme solution (0.1 mg/mL) to the 
protein mixture and incubated for 16 hours at 37°C. The diges-
tion process was arrested by adding 1µL of 10% trifluoracetic 
acid (TFA) to the digestion mixture. Afterwards, samples were 
frozen and stored at -81°C until the MS and MS/MS analysis. 
Protein identification by MALDI-tOF/tOF- mass 
spectrometry
Our study used the AnchorChip Standard (800 mm, 
Bruker, Germany) target plate. As a mass standard in these 
experiments, the Peptide Calibration Standard II (Bruker, Ger-
many) was used. The defined masses of calibrates allowed for 
the proper calibration of the apparatus and covered the mass 
range of 700–3500 Da.  Each of the vaginal fluid samples from 
both the cancer patients and the control subjects was sepa-
rated and fractionated using the reversed phase nano-liquid 
chromatography technique (Easy nanoLC, Bruker, Germa-
ny). The nanoLC apparatus was equipped with: pre-column 
(C18, 5 µm, 120Å, L = 20 mm, NS-MP 10 BioSphere) and bioana-
lytical nano chromatographic column (C18, 75 mm × 15 cm, 
3 µm, 100Å) (Acclaim PepMap, Thermo Scientific). The follow-
ing mobile phases were used: A) 0.05% TFA in water and B) 
0.05% TFA in 90% acetonitrile. Analytes were eluted from the 
analytical column at 300 nL/min flow during a 96-minute 
linear gradient from 2% to 50% of the mobile phase B. The 
eluent was mixed with HCCA (α-cyano-4-hydroxycinnamic 
acid) matrix and spotted onto AnchorChip standard plates 
(800 mm, Bruker, Germany). The 384 fractions with a 15-sec-
ond deposition were automatically collected on the target 
plates using the PROTEINEER apparatus (Bruker, Germany). 
The mass spectrometry experiments were performed 
with the MALDI-TOF/TOF apparatus (UltrafleXtreme, Bruker), 
equipped with FlexControl and FlexAnalysis modules, that 
allowed for data acquisition and data/spectra analysis. The 
MS spectra were acquired in the mass range of 700–3500 Da 
and analyzed using the MALDI-TOF/TOF mass spectrometry 
instrument (Bruker, UltrafeXtreme, Germany) using a fixed 
laser intensity and 2500 shots per spectrum. 
We used the Peptide Calibration Standard II (Bruker, Ger-
many) as the mass standard in these experiments. Prior to each 
MS-analysis, the apparatus was calibrated according to the ref-
erence masses that included: bradykinin 1–7 (m/z 757.3992 Da), 
angiotensin I and II (1046.5418 and 1296.6848 Da, respec-
tively), substance P (1347.7354 Da), bombesin (1619.8223 Da), 
renin substrate (1758.9326 Da), ACTH clip1-17 and ACTH 
clip 18–39 (2093.0862 and 2465.1983 Da, respectively), and 
somatostatin 28 (3147.4710 Da).
Based on the list of masses obtained during the MS 
experiments, the MS/MS mode was applied. Protein iden-
tification was performed with the ProteinScape and Mascot 
platform using the SwissProt database, and results with less 
than 1% FDR (false discovery rate) were taken into considera-
tion. The following protein modifications were taken into the 
consideration: carbamidomethyl, oxidation, acetyl (N)-term 
and Glu- > pyro-Glu (N-term E). Protein identification search 
parameters were set as follows: peptide tolerance 50 ppm 
and peptide charge +1; and up to 1 missed cleavage was 
permitted. 
rEsULts
Our study was designed to focus on protein profile iden-
tification in cervico-vaginal fluid taken from ovarian cancer 
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patients in comparison with samples from healthy control 
group subjects.
Using MALDI-TOF/TOF mass spectrometry (MS/MS) ex-
periments we identified 404 different proteins in the cancer 
CVF samples and a further 417 different proteins in the CVF 
samples from the control group. At the very beginning of the 
study, all the proteins that we identified were divided into 
three separate classes: those common to both the cancer 
and control groups, those unique to the cancer group, and 
those unique to the control group. 
Detailed comparison of the proteins identified in both 
the cancer and control group samples enabled the selection 
of 239 different proteins that were common to both the 
cancer and the control samples; 178 different proteins that 
were unique to the control group, and 165 different proteins 
that were unique to the cervico-vaginal fluid samples de-
rived from the cancer patients. Moreover, we used the Pan-
ther Classification System program to analyze the proteins 
groups according to their molecular functions, biological 
processes, cellular components, protein class and path-
ways [5]. Those proteins that were characteristic of cancer 
were identified (Tab. 1) and those found in at least 4 (50%) 
of the samples were identified (Tab. 2) and all these were 
analyzed according to their molecular functions, biological 
processes, cellular components, protein class and biological 
pathways. (Fig. 1). However, we particularly focused our at-
tention on three different proteins: cysteine-rich secretory 
protein 3, fibronectin, and Ly6/PLAUR domain-containing 
protein 3, due to their presence in 5 of the 8 ovarian cancer 
samples we analyzed and because of their particular bio-
logical properties.
DIsCUssION
Human cervico-vaginal fluid (CVF) is a mixture of flu-
ids originating from the vagina, cervix, endometrium and 
oviduct [6]. Its composition is influenced by many factors, 
both hormonal changes during the menstrual cycle, as well 
as pathogens present in the reproductive tract [4]. Cervi-
co-vaginal fluid can be considered as a potential source of 
genital tract biomarkers. The secretion is readily available [7]. 
For several years, interest in vaginal and cervical secretions, 
as potential sources of ovarian cancer markers, has been 
increasing. In 1978, there were cases presented that showed 
that the presence of cancer cells in cytology cervical smears 
was caused by advanced ovarian and fallopian cancer [8]. 
Cytological changes caused by ovarian cancer have even 
occurred in 19.3% of patients in the absence of changes in 
the cervix and endometrium. The percentage of positive 
smears of lavage fluid from the uterine cavity was even 
higher [9,10]. Positive cytology results were usually found 
in the serous type of advanced ovarian cancer (HGSC) co-
existing with ascites [11]. Microscopic assessment of CVF is 
table 1. Classification of proteins identified as unique to the cancer 
group due their molecular functions, biological processes, cellular 
components, protein class and biological pathways
Molecular Function
Binding (GO:0005488) 44
Receptor activity (GO:0004872) 2
Structural molecule activity (GO:0005198) 5
Signal transducer activity (GO:0004871) 3
Catalytic activity (GO:0003824) 31
Transporter activity (GO:0005215) 5
Biological process
Cellular component organization or biogenesis (GO:0071840) 17
Cellular process (GO:0009987) 62
Localization (GO:0051179) 16
Biological regulation (GO:0065007) 18
Response to stimulus (GO:0050896) 18
Developmental process (GO:0032502) 16
Multicellular organismal process (GO:0032501) 14
Biological adhesion (GO:0022610) 5
Locomotion (GO:0040011) 1
Metabolic process (GO:0008152) 51
Immune system process (GO:0002376) 7
Cellular component
Synapse (GO:0045202) 1
Cell junction (GO:0030054) 3
Membrane (GO:0016020) 18
Macromolecular complex (GO:0032991) 7
Extracellular matrix (GO:0031012) 1
Cell part (GO:0044464) 41
Organelle (GO:0043226) 29
Extracellular region (GO:0005576) 5
Protein class
Transporter (PC00227) 3
Transmembrane receptor regulatory/adaptor protein (PC00226) 1
Membrane traffic protein (PC00150) 1
Hydrolase (PC00121) 13
Oxidoreductase (PC00176) 4
Cell adhesion molecule (PC00069) 4
Cell junction protein (PC00070) 3
Enzyme modulator (PC00095) 13
Transfer/carrier protein (PC00219) 4
Transferase (PC00220) 2
Transcription factor (PC00218) 3
Nucleic acid binding (PC00171) 9
Defense/immunity protein (PC00090) 4
Calcium-binding protein (PC00060) 4
Cytoskeletal protein (PC00085) 7
Signaling molecule (PC00207) 10
→
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an imprecise method in comparison with analyses of pro-
tein composition [12]. Only a limited number of proteomic 
studies using mass-spectrometry have been performed on 
cervico-vaginal fluid [7]. Analysis of CVF proteins was used 
in the identification of biomarkers for premature delivery, 
premature rupture of membranes, bacterial vaginosis and 
even cervical cancer [4, 13]. Our study is the first proteomic 
analysis of cervico-vaginal fluid in ovarian cancer patients 
known to the authors, which has allowed the detection 
of new potential markers, that may be useful for the early 
diagnosis and progress monitoring of ovarian cancer.  
For our preliminary proteomic study of ovarian can-
cer, we used MALDI-TOF/TOF MS/MS mass spectrometry 
coupled with the nanoLC technique for sample analy-
sis. MALDI-TOF/TOF MS/MS is very fast and sensitive for 
proteomics analysis and it allows for a high throughput of 
protein identification [14]. However, it must be emphasized, 
that the presence of proteins identified by MALDI-TOF/TOF 
needs to be confirmed by other bioanalytical methods 
(e.g. immuno-assay methods). 
The results of our study showed three proteins that 
can potentially differentiate patients with ovarian cancer 
from healthy patients: fibronectin, cysteine-rich secretory 
protein 3 and Ly6/PLAUR domain-containing protein 3. In 
ovarian cancer (OC), fibronectin has a well-established role 
in cancer metastasis. It has antiapoptotic functions, and 
promotes angiogenesis and the adhesion of OC cells to the 
peritoneal surface [15].
Cysteine-rich secretory protein3 (CRISP3) is involved 
in defense and immunity processes [16]. The expression 
of CRISP3 has been shown to be highly up-regulated in 
prostate cancer. It is associated with poor prognoses due to 
its role in cell invasion. Cysteine-rich secretory proteins are 
table 2. List of proteins that differentiate the ovarian cancer group 
(serous ovarian cancer, mucinous ovarian cancer and borderline 
tumor) and control group
Diagnosis
Protein
sOC
(n = 5)
MOC
(n = 2)
Bt
(n = 1)
Alpha-2-macroglobulin-like protein 1 3
Serpin B-13 4
Acyl-CoA-binding protein 4
Calmodulin-like protein 5 3
Cytidine deaminase 2 1
Cysteine-rich secretory protein 3 4 1
Fibronectin 2 2 1
Interleukin-1 receptor antagonist 
protein 4
Ly6/PLAUR domain-containing protein 3 5
SOC — serous ovarian cancer; MOC — mucinous ovarian cancer; BT 
— borderline tumor, n — number of subjects in analyzed group
table 1. cont. Classification of proteins identified as unique to the 
cancer group due their molecular functions, biological processes, 
cellular components, protein class and biological pathways
Pathway
Axon guidance mediated by netrin (P00009) 2
Axon guidance mediated by Slit/Robo (P00008) 1
Axon guidance mediated by semaphorins (P00007) 1
Apoptosis signaling pathway (P00006) 2
Angiogenesis (P00005) 2
Alzheimer disease-presenilin pathway (P00004) 4
Integrin signalling pathway (P00034) 6
Inflammation mediated by chemokine and cytokine signaling 
pathway (P00031) 4
Hypoxia response via HIF activation (P00030) 1
Nicotine pharmacodynamics pathway (P06587) 1
Huntington disease (P00029) 1
p53 pathway (P00059) 1
Heterotrimeric G-protein signaling pathway-Gq alpha and Go 
alpha mediated pathway (P00027) 3
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs 
alpha mediated pathway (P00026) 1
Wnt signaling pathway (P00057) 2
VEGF signaling pathway (P00056) 1
Ras Pathway (P04393) 1
T cell activation (P00053) 1
FGF signaling pathway (P00021) 1
ATP synthesis (P02721) 1
Plasminogen activating cascade (P00050) 1
Endothelin signaling pathway (P00019) 1
EGF receptor signaling pathway (P00018) 1
DNA replication (P00017) 1
Parkinson disease (P00049) 1
Cytoskeletal regulation by Rho GTPase (P00016) 2
PDGF signaling pathway (P00047) 2
Oxidative stress response (P00046) 1
Histamine H1 receptor mediated signaling pathway (P04385) 1
Cadherin signaling pathway (P00012) 1
Blood coagulation (P00011) 1
Dopamine receptor mediated signaling pathway (P05912) 1
Salvage pyrimidine ribonucleotides (P02775) 1
B cell activation (P00010) 2
Muscarinic acetylcholine receptor 1 and 3 signaling pathway 
(P00042) 1
Angiotensin II-stimulated signaling through G proteins and 
beta-arrestin (P05911) 2
Salvage pyrimidine deoxyribonucleotides (P02774) 1
CCKR signaling map (P06959) 3
Pyrimidine Metabolism (P02771) 1
Gonadotropin-releasing hormone receptor pathway (P06664) 2
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Figure 1. Graphic presentation of the functional classification (molecular functions, biological processes, cellular components, protein class and 
biological pathways) of all the proteins selected as characteristic of ovarian cancer patients gathered and presented at Table 1
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strongly expressed in lung adenocarcinoma tissues where 
they promote the migration and invasion of carcinoma 
cells [17]. Also high expression of CRISP3 is found in ovar-
ian cancer tissue. However, its role and importance in this 
disease is unknown [18, 19]. 
Ly6/PLAUR domain-containing protein3 (LYPD3) has 
been identified in non-small cell lung cancer, colorectal and 
breast cancer. It seems to be involved in cell migration, inva-
sion and tumor progression [20–22]. LYPD3 protein deserves 
special attention because it occurred in all the serous OC 
samples in our study. It can be a marker of the most lethal 
serous type of ovarian cancer and enables recognition of 
this disease at all stages. 
The proteins selected in our pilot study seem to be of 
great interest and to be potentially valuable markers for 
early ovarian cancer diagnosis. They may help in screening 
patients with BRCA mutation and differentiate healthy from 
ovarian cancer patients. However, further investigations 
will be necessary to prove their suitability and value as 
non-invasive biomarkers. It is strongly recommended that 
these possibilities are tested in large population studies so as 
to determine the levels of these proteins in vaginal fluid sam-
ples derived from ovarian cancer patients at various tumor 
progression stages when compared with control samples.
CONCLUsIONs
There is a characteristic proteomic pattern in the 
cervico-vaginal fluid of patients with ovarian carcinoma, 
which may allow the differentiation of cancer patients 
from healthy patients. Our findings indicated 3 proteins 
in the cervico-vaginal fluid of ovarian cancer patients: fi-
bronectin, cysteine-rich secretory protein3 and Ly6/PLAUR 
domain-containing protein3. These proteins show a strong 
potential to be used in multi-marker tests for the screening 
and detection of ovarian cancer. Our findings provide the 
basis for further research aimed at the early diagnosis of 
ovarian cancer and the reduction of mortality due to this 
disease.
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